Medical articles today

/* 728x15, */

Studies Identify Significant Findings In Treating People Living With GI Cancers

Seven additional studies on the early detection, treatment and prevention of gastrointestinal cancers were highlighted today by the co-sponsoring organizations of the 2010 GI Cancers Symposium. The symposium is being held January 22-24 at the Orlando World Center Marriott in Florida. Abstract 3 Transhiatal approach is superior to left thoracoabdominal approach for treating certain forms of esophageal and gastric cancer: Researchers have confirmed that the abdominal and transhiatal (AT) approach is superior to the left thoracoabdominal (LT) approach for surgical treatment of two forms of esophagogastric cancer (cancer of the junction between the stomach and esophagus), called true cardia and sub-cardia cancer.

Data Show Progression-Free Survival Advantage With Sutent R In Patients With Pancreatic Neuroendocrine Tumors

Pfizer Inc. announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas. Sunitinib more than doubled the time patients with pancreatic neuroendocrine tumors lived without disease progression compared with patients treated with placebo, according to study findings that will be presented tomorrow at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in Orlando, Florida. An independent Data Monitoring Committee (DMC) recommended halting the trial in February 2009 because sunitinib showed significant benefit and the primary endpoint was met.

/* 468x60, */

ASCO-GI: Overall Survival With Erbitux Is Significantly Improved In Patients With KRAS Wild-Type Tumors In CRYSTAL

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.1 In addition, the final results from this study included an analysis of the predictive value of BRAF status on Erbitux efficacy - one of the first to be based on a large subgroup (n=59) of a prospective, randomized study in the 1st-line setting. The analysis indicates that patients with KRAS wild-type tumors bearing a BRAF mutation also benefit from Erbitux treatment;

What Is Rotavirus Gastroenteritis? What Causes Rotavirus Gastroenteritis?

Rotavirus gastroenteritis is a virus that infects the stomach and intestine. It is spread by infected people who do not wash their hands properly after going to the toilet and by contact with tiny samples of infected feces. Rotavirus is transmitted by the fecal-oral route. It is the most common cause of severe diarrhea in infants and children worldwide. It is estimated that every child will have at least one rotavirus infection before the age of five. Most infections occur among children aged between three months and three years of age. Gastroenteritis can have a number of causes, such as bacterial infection or food poisoning. The rotavirus is the leading cause of gastroenteritis in children.

Canada's Food Safety System Fails International Comparisons

Canada's food safety system is reactive, lags behind other countries, and investment is needed to ensure it can adequately protect Canadians, states an article in CMAJ (Canadian Medical Association Journal). Foodborne illness surveillance is needed to ensure safety from gastrointestinal infections caused by bacteria such as toxigenic E.coli, Salmonella, Campylobacter and Listeria. As there is no national foodborne illness surveillance program in Canada, the estimated 11 million cases of foodborne illness every year are based on surveys of self-reported gastrointestinal illness. More accurate data are needed to execute meaningful intervention.

/* 468x60, */

Discovery Of Link Between Stomach-Cancer Bug And Cancer-Promoting Factor

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer. Chronic infection with H. pylori is a well-documented risk factor for several forms of gastric cancer, but researchers have not yet determined the mechanisms by which specific bacterial factors contribute to cancer development. Nearly one-half of the world's population is infected with H. pylori, and gastric cancer is one of the leading causes of cancer-related death. The new study, in Proceedings of the National Academy of Sciences, is the first to show that a factor produced by the bacterium directly activates poly(ADP-ribose) polymerase-1 (PARP-1), an enzyme found primarily within the nucleus of animal cells.

/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy